(BUSINESS WIRE)--NeurOp, Inc., headquartered in Atlanta, Georgia, is a preclinical-stage pharmaceutical company developing innovative therapeutics for central nervous system disorders, including depression, neuropathic pain and ischemia. The company’s most advanced compounds modulate a well-validated target, the NMDA receptor, in a manner designed to enhance therapeutic benefit while alleviating side effects associated with previous-generation NMDA receptor antagonists. For more information, please visit www.neuropinc.com.
